BPMC News and Press, Blueprint Medicines Corporation From 05/13/24

2024-05-13 18:15:03 ET Stephens analyst issues OVERWEIGHT recommendation for BPMC on May 13, 2024 04:31PM ET. BPMC was trading at $108.05 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 3 - Hold ...

2024-05-09 15:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-04 07:43:58 ET Summary Blueprint Medicines generates growing revenues from its FDA-approved product AYVAKIT/AYVAKYT. AYVAKIT has been approved for multiple indications, including gastrointestinal stromal tumor and systemic mastocytosis. Blueprint reported strong Q1 202...

A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 30.3% to $0.2932 on volume of 173,918,707 shares Emergent Biosolutions Inc. (EBS) rose 71.0% to $3.3 on volume of 150,987,238 shares PROSHARES TRUST (SQQQ) fell 3.6% to $11.78 on volume of 136,332,744 sh...

2024-05-02 13:42:09 ET Blueprint Medicines Corporation (BPMC) Q1 2024 Earnings Conference Call May 02, 2024 08:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Off...

A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 97.8% to $2.71 on volume of 44,141,232 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 1.1% to $0.0456 on volume of 28,670,184 shares Emergent Biosolutions Inc. (EBS) rose 67.7% to $3...

2024-05-02 07:09:41 ET More on Blueprint Medicines Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade) Blueprint Medicines Corporation (BPMC) Q4 2023 Earnings Call Transcript Blueprint Medicines Q1 2024 Earnings Preview Blueprint Medici...

Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...

2024-05-01 14:30:27 ET More on Blueprint Medicines Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade) Blueprint Medicines Corporation (BPMC) Q4 2023 Earnings Call Transcript Blueprint Medicines Q4 2023 Earnings Preview Seeking Alpha&#x...

2024-04-29 07:00:00 ET Summary Rigel Pharmaceuticals has multiple approved agents and a modest pipeline of developmental projects. The company has a stable financial position with growing sales and a new product in its stable. Rigel Pharmaceuticals faces both strengths and ris...